HESLOP, Helen E. 
Pr| ncipal Investigatof/Program Director (Last, firs t, middle): 
R°w e M ' Rooney CM, Edwards CG, Lenoir GM, Rickinson AB. Epstein-Barr virus status and 
tumour cell phenotype in sporadic Burkitt ' s lymphoma. Int J Cancer 37:363-372, 1986. 
Miller G, Grogan E, Rowe D, Rooney C, Heston L, Eastman R, Andiman W, Niederman J, Lenoir 
G, Henle W, Sullivan J, Schooley J, Vossen J, Straus S, Issekutz T. Selective lack of 
antibody to the Bam HI K component of EB nuclear antigen in some patients with chronic 
active Epstein-Barr virus infection. J Infect Dis 156 ( 1 ): 26-35 , 1987. 
Young LS, Yao QY, Rooney CM, Sculley TB, Moss DJ, Rupani H, Laux G, Bornkamm GW, 
Rickinson AB. New type B isolates of Epstein-Barr virus from Burkitt 's lymphoma and from 
normal individuals in endemic areas. J Gen Virol 68:2853-2862, 1987. 
Rooney CM, Taylor N, Countryman J, Jenson H, Kolman J, Miller G. Genome rearrangements 
in a defective Epstein-Barr virus activate a gene whose product disrupts latency. Proc 
Natl Acad Sci 85:9801-9805, 1989. 
Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF1 transactivator 
is a member of the jun oncogene family. EMBO J 8 ( 7 ) : 127-132 , 1989. 
Rooney C, Howe JG, Speck SH, Miller G. Influences of Burkitt 's lymphoma and primary B 
cells on latent gene expression by the non-immortalizing P3J-HR-1 strain of Epstein-Barr 
virus. J Virol 63 ( 4 ): 1531-1539 , 1989. 
Taylor N, Countryman J, Rooney C, Katz D, Miller G. Expression of the BZLF1 latency- 
disrupting gene differs in standard and defective Epstein-Barr viruses. J Virol 
63(4) :1721-1728, 1989. 
Rooney CM, Rowe DT, Ragot T, Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus 
(EBV) transactivates an early EBV promotor and induces the virus productive cycle. J 
Virol 63(7) :3109-3116, 1989. 
Farrell PJ, Rowe DT, Rooney CM, Kouzarides T. Epstein-Barr virus BZLF1 transactivator 
specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8:127-133, 
1989. 
Miller G, Taylor N, Countryman J, Rooney C, Katz D, Kilman J, Jenson H, Grogan E, 
Gradoville L. Role of the Zebra protein in the switch between Epstein-Barr virus latency 
and replication. In: Ablashi DV, Faggioni A, Krueger GRF , Pagano JS, Pearson GR, eds. 
Epstein-Barr virus and human disease. Clifton, New Jersey: Humana Press, pp 17—36, 1989. 
Packham G, Economou A, Rooney CM, Rowe DT, Farrell PJ. Structure and function of the 
Epstein-Barr virus BZLF1 protein. J Virol 64 ( 5 ): 2110-2116 , 1990. 
Buschle M, Brenner MK, Chen ISY, Drexler HG, Gignac SM, Rooney CM. Transfection and gene 
expression in normal and malignant primary B lymphocytes. J Immunol Meth 133:77-85, 
1990. 
Rooney CM, Baker B. Patients with psoriasis have a high frequency of antibodies to EBNA- 
2B. In: Ablashi, Faggioni, Krueger, Pagano, Pearson, eds. Epstein Barr virus and human 
disease. New Jersey: Humana Press, 1990. 
Rooney CM, Brimmel M, Allan G, Farrell P, Buschle M. Control of latent cycle promoter 
selectivity. In.: Ablashi, Faggioni, Krueger, Pagano, Pearson, eds. Epstein Barr virus 
and human disease. New Jersey: Humana Press, 1990. 
Rooney CM, Brimmell M, Buschle M, Allan G, Farrell P, Kolman J. Host cell and EBNA-2 
regulation of Epstein-Barr virus latent cycle promoter activity in B lymphocytes. J 
Virol 66 ( 1 ): 496-504 , 1992. 
Stewart JP, Rooney CM. The interleukin-lOn (IL-10) homologue encoded by the Epetein-Barr 
virue BCRF-1 open-reading trace (viral IL-10) enhances the reactivation of virue-specif ic 
p en and atLi.aLHU mihi^n lespuim t u. vir o l og y 101:773 701, 1003. . 
PHS t uyl1 ‘ mJ ‘‘Liiuated Lill-.p^ll 
Number pa R^e^i!^t e I^N7V h Re , seat , dFp li V'ohmifp' suf,ixes s,jch a " 3a 3b 
[ 229 ] 
